Covid-19 roundup: Pfizer raises 2021 vaccine sales forecast to $36B; Lilly lands $1.3B treatment deal with US government
Pfizer’s Covid-19 vaccine in 2021 is quickly becoming the best-selling medical product of all time in terms of annual sales.
The company on Tuesday reported its quarterly earnings and re-upped its yearly guidance on its Covid-19 vaccine sales, saying the company anticipates $36 billion in 2021, up from its $33.5 billion estimate in July. The company expects to deliver a whopping 2.3 billion doses of its vaccine in 2021, but it expects to manufacture 3 billion doses in total by the end of December.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.